News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aegis Therapeutics, LLC Awarded 2nd Patent for Fast Acting Migraine Nasal Spray Treatment



5/14/2013 9:30:17 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!


SAN DIEGO, May 14, 2013 /PRNewswire-iReach/ -- Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,440,631, its second patent providing fast acting formulations for triptans, a class of drugs that are effective in treating migraine headaches which include sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan. Human clinical trials have shown that the Intravail® formulation of sumatriptan achieves therapeutic drug levels at approximately 2 to 3 minutes, 20 to 30 times faster that the currently marketed non-injectable sumatriptan products. For comparison, the most widely used triptan formulations, namely sumatriptan nasal spray or tablet formulations, both reach maximum blood levels of drug in about 60 to 120 minutes thus delaying onset of relief.

The enabling Aegis Intravail formulation technology is broadly applicable to a wide range of small molecule and biotherapeutic drugs to increase noninvasive bioavailability by the oral, nasal, buccal, and sublingual routes and to speed attainment of therapeutic drug levels in cases where speed is important to the patient, for example in the treatment of pain, nausea, emesis, convulsive disorders, spasticity, and the like.

Aegis technology is commercialized by our licensees who conduct the actual product development and marketing activities. Aegis' licensees include four of the top 10 largest pharmaceutical companies and two of the top 10 largest generics companies, along with many public and private biotech companies. Aegis growing patent portfolio currently has more than fifty issued and pending drug formulation patents covering peptide, protein, and small-molecule drugs.

About Aegis Therapeutics
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability. Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding the oxidative damage caused by polysorbate surfactants.

For more information about Aegis, please visit: http://www.aegisthera.com.

Press release submitted by Submit Press Release 123.com's press release distribution service

Media Contact: Ralph Barry, Aegis Therapeutics LLC, 858 618-1400 Ext 102, rbarry@aegisthera.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Aegis Therapeutics LLC



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES